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Abstract
Purpose Paclitaxel-based chemotherapy continues to be an
integral component in the treatment of many solid tumors.
Prolonged use of paclitaxel may result in repeated doses of
premedications and potential unwanted side effects. Infusion
hypersensitivity reactions occurring beyond the second dose
are infrequent and not well characterized. We hypothesized
that patients whose paclitaxel premedications were discon-
tinued after two doses were unlikely to experience infusion
hypersensitivity reactions with subsequent paclitaxel doses.
Methods Patients receiving paclitaxel-based chemotherapy
who did not experience an infusion hypersensitivity
reaction with their first or second dose had their paclitaxel
premedications discontinued. The primary endpoint was to
estimate the incidence of rescue medication for the
treatment of paclitaxel infusion hypersensitivity during
doses 3 to 6 for patients whose paclitaxel premedications
had been discontinued.
Results After receiving the first two doses of paclitaxel-
based chemotherapy without experiencing an infusion
hypersensitivity reaction (any grade), 55 breast cancer
patients had their premedications discontinued for all
remaining paclitaxel doses. None of these patients required
rescue medication to treat an infusion hypersensitivity
reaction with subsequent doses.
Conclusions In patients who have not experienced an
infusion hypersensitivity reaction with the first two doses of
paclitaxel, discontinuation of paclitaxel premedications may
be considered an option without an increased risk of infusion
hypersensitivity requiring rescue medication.
Keywords Abbreviated . Paclitaxel . Premedication .
Prophylaxis . Hypersensitivity
Introduction
Paclitaxel is commonly used in the treatment of a variety of
solid tumors. More recently, the use of weekly paclitaxel has
demonstrated superior efficacy and tolerability in the treat-
ment of early stage and metastatic breast cancer [1, 2]. Due to
its hydrophobic properties, paclitaxel must be emulsified in a
vehicle consisting of 50% polyoxyethylated castor oil
(Cremophor EL) and 50% ethanol. Despite premedication
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with a corticosteroid and both histamine-1 and histamine-2
receptor antagonists, hypersensitivity reactions (all grades)
during intravenous administration of paclitaxel (135 to
300 mg/m2 as a 3- or 24-h infusion) for the treatment of
solid tumors in clinical studies occurred in 41% of patients,
and “severe” (grade 3 or higher) hypersensitivity reactions
occurred in 2% of patients [3]. Recent literature using
paclitaxel for the treatment of breast cancer at doses between
80 and 90 mg/m2 given as a 1-h infusion report a similar
incidence (less than 3%) of grade 3 or higher hypersensitivity
reactions [1, 4].
Previous studies have demonstrated that a simplified,
intravenous premedication regimen consisting of dexametha-
sone and both histamine-1 and histamine-2 receptor antago-
nists administered 30 min prior to paclitaxel infusion can
successfully reduce the incidence and severity of these
reactions with comparable clinical efficacy to older regimens
that employed dexamethasone 20 mg given orally 12 and 6 h
and immediately prior to paclitaxel, although some remain
critical of this simplified approach [5–7]. The most frequently
used corticosteroid in the prevention of paclitaxel-induced
hypersensitivity reactions is dexamethasone, which is among
the most potent and longest acting of the corticosteroids.
With prolonged use of paclitaxel, especially when given in a
once weekly fashion, patients are exposed to repeated doses
of dexamethasone. Side effects associated with short-term
and prolonged use of corticosteroids are well documented,
including hyperglycemia, insomnia, gastritis, fluid retention,
weight gain, immune suppression, acne, skin changes,
osteoporosis, mental status changes, and adrenal suppression.
In addition, when administered as an intravenous bolus,
dexamethasone has been associated with perianal pruritis.
Diphenhydramine, the most commonly employed histamine-
1 receptor antagonist for the prevention of paclitaxel-induced
hypersensitivity, is commonly associated with drowsiness
and can paradoxically cause dystonia and restlessness when
50 mg is administered intravenously [8].
To minimize the adverse effects of corticosteroids, several
strategies exploring an alternative paclitaxel premedication
regimen have been published including incorporation of a
paclitaxel test dose, dexamethasone dose reduction, or use of a
dexamethasone tapering schedule [9–12]. In an attempt to
further simplify paclitaxel premedication and avoid unnec-
essary side effects caused by premedication regimens, we
hypothesized that discontinuing paclitaxel premedications
after the first two doses of paclitaxel would not result in an
increased usage of rescue medications to treat infusion
hypersensitivity reactions for subsequent paclitaxel doses.
This is in contrast to standard paclitaxel premedication
regimens in which patients may continue to receive premed-
ications prior to each dose of paclitaxel, even if they had not
experienced a previous infusion hypersensitivity reaction. To
test this hypothesis, a clinical trial was designed.
Materials and methods
Patients Eligibility criteria included patients ≥18 years old
able to give informed consent and scheduled to receive at
least four doses of paclitaxel as a single agent or in
combination with trastuzumab, bevacizumab, gemcitabine,
or other drug combination (excluding cisplatin or carboplatin)
for the treatment of any stage breast cancer; patients receiving
concurrent radiation; patients currently enrolled in another
clinical trial provided that the other trial did not prohibit the
discontinuation of paclitaxel premedications; and patients
receiving intermittent oral steroids for nausea or for acute
inflammatory conditions (i.e., methylprednisolone Dosepak)
and inhaled, intranasal, or topical corticosteroids were also
eligible. Exclusion criteria included patients receiving thera-
peutic daily doses of systemic corticosteroids; patients
receiving paclitaxel albumin bound; history of grade 3
hypersensitivity reaction to Cremophor EL-containing medi-
cations (paclitaxel, cyclosporine, ixabepilone, teniposide),
docetaxel or paclitaxel albumin bound; patients who had
received at least one dose of paclitaxel, docetaxel, or
paclitaxel albumin bound within the last 12 months; patients
receiving paclitaxel in combination with carboplatin or
cisplatin (due to risk of hypersensitivity with platinum
compounds); and patients who were pregnant. The
research protocol was approved by the cancer institutional
review board. All patients provided written informed
consent prior to receiving their first dose of paclitaxel-
based chemotherapy.
Treatment Enrolled patients beginning paclitaxel-based che-
motherapy received standard paclitaxel premedications (dexa-
methasone 20 mg IVP, diphenhydramine 50 mg IVP, and
famotidine 20 mg IVP) all given at least 30 min prior to the
start of paclitaxel. If a patient was receiving paclitaxel in
combination with other chemotherapy, the paclitaxel was
infused first. For paclitaxel doses less than 100 mg/m2, the
drug was added to a DEHP-free infusion container of 0.9%
NaCl or 5% dextrose water 250 mL and infused over
60 min. For paclitaxel doses more than 100 mg/m2, the drug
was added to a DEHP-free infusion container of 0.9% NaCl
or 5% dextrose water 500 mL and infused over 180 min. If
patients did not experience an infusion hypersensitivity
reaction (any grade) with either of the first two paclitaxel
(doses), dexamethasone, diphenhydramine, and famotidine
were discontinued prior to the third dose and for all
subsequent paclitaxel doses. Patients who experienced an
infusion hypersensitivity reaction (any grade) with the first or
second dose of paclitaxel (regardless if rescue medication
was administered) were not eligible to have their premed-
ication regimen discontinued. Patients receiving subsequent
doses of paclitaxel after premedications were discontinued
who experienced an infusion hypersensitivity reaction were
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to have paclitaxel premedications reinstituted and managed
at the discretion of the prescribing physician.
Endpoints and assessment The primary endpoint was to
estimate the incidence of rescue medication usage during
paclitaxel doses 3 through 6 for patients whose premed-
ication regimen was discontinued. Previous studies have not
adequately defined what constitutes a “severe” or “clinically
relevant” infusion reaction, what scale/scoring system was
used to grade them, and how many patients actually received
parenteral rescue medications to treat these reactions. We
selected the use of rescue medication as our primary endpoint,
rather than occurrence of an infusion hypersensitivity reaction,
because the former is a more measurable endpoint given the
difficulty of grading these reactions.
Clinical signs and symptoms of paclitaxel hypersensi-
tivity reactions (Table 1) may vary. Grading of these
hypersensitivity reactions is challenging due to the fact that
no standard criteria have been developed: NCI Common
Toxicity Criteria for Adverse Events (CTCAE) Version 3.1 for
“Allergic Reaction/Hypersensitivity” (Table 2) was not all
encompassing; for example, paclitaxel infusion hypersensi-
tivity may also include diaphoresis, anxiety, tachycardia,
symptomatic chest pain, and back pain. Furthermore, in
routine clinical practice, parenteral “rescue” medications are
often administered at the onset of the infusion hypersensi-
tivity reaction to minimize the severity and progression of
the reaction. Therefore, the use of parenteral medications in
symptomatic patients is not restricted to CTCAE grade 3
(and higher) reactions only.
During paclitaxel infusions, patients experiencing any of
the symptoms listed (Table 1) were considered to have
experienced an infusion hypersensitivity reaction. The use of
rescue medication for the treatment of paclitaxel infusion
hypersensitivity was defined as the administration of at least
one parenteral rescue medication (excluding 0.9% sodium
chloride) including hydrocortisone, diphenhydramine, or
epinephrine. Each patient’s electronic chemotherapy order
contained standing orders enabling the chemotherapy nurse
to identify and treat a hypersensitivity reaction as follows:
stop the infusion, call an additional nurse into the room,
notify the physician, and administer hydrocortisone 50 mg
IVP and diphenhydramine 50 mg IVP. If at any time the
patient exhibits severe signs of angioedema or broncho-
spasm, administer epinephrine 0.3 mg IM, call the physician
to discuss further management of the reaction including
fluids, oxygen, and reinitiation of the infusion if the reaction
resolves. Patients were monitored for an infusion hypersen-
sitivity reaction and rescue medication usage and had data
recorded for up to six doses of paclitaxel, after which time
the patient’s data collection for the trial was completed as the
incidence of infusion hypersensitivity reactions beyond this
point would be increasingly rare. Paclitaxel lot numbers and
manufacturer information were recorded by the pharmacy
staff. The chemotherapy nurses were not blinded; they knew
what dose number of paclitaxel the patient was receiving and
whether or not the patient was receiving premedication. The
chemotherapy nurse remained in the patient room during the
first 10 min of the paclitaxel infusion for the first three doses
to closely monitor for any grade hypersensitivity reaction.
The patient had a call button to alert the nurse for problems
occurring when the nurse was not present.
Statistical analysis This observational study was designed
to enroll 70 subjects to estimate the incidence of rescue
medication required for paclitaxel doses 3 through 6.
Assuming 20% of patients would not be eligible for our
primary analysis due to various reasons (including hyper-
sensitivity with the first two doses), 54 subjects would be
needed to estimate the incidence. Although the incidence is
thought to be low, the true incidence of rescue medication
usage after the second dose is unknown; a 0% to 5%
incidence of rescue medication during doses 3 to 6 was
considered acceptable. If 3 of the 54 subjects who had
paclitaxel premedications discontinued would require rescue
medication during doses 3 to 6, the incidence would be 5.6%
with a 95% confidence interval of 1.2% to 15.4%. No
inferential testing was done to compare this incidence rate to
historical controls as these rates are not known. Consequently
no formal power analysis was used to estimate the sample
size. If any patients required rescue medication after the
discontinuation of paclitaxel premedications, an exact logistic
regression analysis would determine if any of the demographics
were associated with the incidence of rescue medication. The
trial was to be stopped if there were 8 or more subjects out of
the first 15 in the protocol population that required rescue
medication. The trial would continue to full accrual if 7 or less
required rescue medication out of the first 15. The probability
of stopping the trial early was <0.001 if the true rescue
medication incidence during cycles 3 to 6 was 5%. If the true
incidence was 15% or 25%, then the probability of stopping
early was 0.001 or 0.017, respectively.
The protocol population, defined as those patients who did
not experience an infusion hypersensitivity reaction (any
grade) with their first two paclitaxel doses and who received
their remaining doses of paclitaxel with no premedications,
was used in the primary analysis of estimating the incidence of
rescue medication in doses 3 through 6. Patients receiving
subsequent doses of paclitaxel after premedications were
Table 1 Symptoms of hypersensitivity reactions
Flushing Hypertension Chest pain Angioedema
Urticaria Hypotension Back pain Anxiety
Rash Dyspnea Abdominal pain
Diaphoresis Tachycardia
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discontinued who experienced an infusion hypersensitivity
reaction requiring rescue medication were to have standard
premedications resumed for later paclitaxel doses and
managed at the discretion of the prescribing physician; these
patients were also included in the primary analysis. Patients
who experienced an infusion hypersensitivity reaction (any
grade) with the first or second dose of paclitaxel (regardless if
rescue medications were administered) were not eligible to
have premedications discontinued and were not included in
the primary analysis.
Results
Baseline characteristics of all 70 enrolled patients are
summarized in Table 3. Patients were enrolled at two
outpatient chemotherapy infusion centers between August
2009 and March 2010. The type of chemotherapy regimen
received is reflected in Table 4. Fifteen (21%) patients were
not included in the primary analysis for the following
reasons: consent withdrawn after the first dose (n=1);
paclitaxel stopped prior to third dose due to paclitaxel
toxicity; pneumonitis and myelosupression accompanied
with refusal to receive blood products (n=2); hypersensi-
tivity reaction experienced with the first dose of paclitaxel
and therefore continued standard paclitaxel premedication
in future cycles (two of these patients were rechallenged
with paclitaxel the same day and successfully completed
their entire course of therapy, while another patient was not
rechallenged but rather changed to paclitaxel albumin bound
given the severity of the infusion hypersensitivity reaction; n=
3); paclitaxel premedications continued for other reasons
despite not having hypersensitivity with the first or second
dose; itching unrelated to infusion, delayed dermatologic
toxicity, and patient preference (n=3); and paclitaxel premed-
ications discontinued after the second dose but requested
premedications be resumed with later doses in hopes of
alleviating noninfusion-related toxicities—plantar skin peel-
ing, lower extremity rash and facial burning, rash on dorsal
arm, itching, indigestion, and allergic rhinitis (n=6).
Fifty-five patients who had paclitaxel premedications
discontinued were included in the primary analysis; none of
these patients required parenteral rescue medication with
subsequent paclitaxel doses, and no infusion hypersensitivity
reactions (any grade) were observed. Of these 55 patients, 47
(85%) were receiving 80–90mg/m2 of paclitaxel and 8 (15%)
were receiving 175 mg/m2. These 55 patients received all
scheduled doses of paclitaxel (314 doses, of which 204 were
administered without paclitaxel premedication). The inci-
dence of parenteral rescue medication in our study was 0.0%
with an exact one-sided binomial 95% confidence interval
of 0.0–5.3%.
Discussion
Paclitaxel infusion hypersensitivity reactions are well charac-
terized; regardless of paclitaxel dose or infusion rate, up to
95% of hypersensitivity reactions occur during the first or
second dose, and in almost all cases the hypersensitivity
reaction develops within the first 5–10min of the infusion [13,
14]. The overwhelming majority of patients who experience
an initial hypersensitivity reaction can successfully resume
and complete paclitaxel treatment [9]. In a pooled toxicity
analysis of over 800 patients receiving paclitaxel as a single
agent for the treatment of solid tumors, no grade 3 or higher
Table 3 Baseline patient characteristics
Age in years, median (range) 51 (31–78)
Female sex, n (%) 69 (99)
Male sex, n (%) 1 (1)
Tumor type
Breast, n (%) 70 (100)
Clinical breast cancer stage
Neoadjuvant, n (%) 14 (20)
Stage I, n (%) 7 (10)
Stage II, n (%) 30 (43)
Stage III, n (%) 14 (20)
Stage IV, n (%) 5 (7)
Weight (kg), median (range) 75 (49–151)
Previous lifetime exposure to paclitaxel,
docetaxel or paclitaxel albumin, n (%)
1 (1)
Chronic medical conditionsa
Yes, n (%) 47 (67)
No, n (%) 23 (33)
a One or more of the following: coronary artery disease, hypertension,
diabetes, depression, bipolar disorder, generalized anxiety disorder,
hyperthyroid, hypothyroid, asthma, COPD, GERD, hyperlipidemia,
osteoarthritis, rheumatoid arthritis, lupus, irritable bowel syndrome,
fibromyalgia, migraine, cerebral palsy, colorectal cancer
Table 4 Chemotherapy regimens
N (%)
Paclitaxel 80 mg/m2 IV every 7 days×12 doses 31 (44)
Paclitaxel 80 mg/m2 IV every 7 days×12 doses +
trastuzumab 4 mg/kg loading dose followed
by 2 mg/kg IV every 7 days
19 (27)
Paclitaxel 175 mg/m2 IV every 14 days×4 doses 10 (14)
Paclitaxel 90 mg/m2 IVon days 1, 8, and 15 every 28 days
indefinitely + bevacizumab 10 mg/kg every 14 days
6 (9)
Paclitaxel 90 mg/m2 IV on days 1, 8, and 15 every
28 days×4 cycles + bevacizumab/placebo
10 mg/kg every 14 days
4 (6)
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paclitaxel infusion hypersensitivity reactions occurred beyond
the third dose [3]. Other investigators observed two patients
(5%) who experienced a “clinically relevant” initial hyper-
sensitivity infusion reaction occurring beyond the second
dose [13]. Paclitaxel hypersensitivity reactions have been
attributed to the vehicle or the drug itself [12, 14]. Interestingly,
paclitaxel albumin bound (Abraxane™) which does not
contain Cremophor EL can be safely administered without
premedications and there were no grade 3 or higher hypersen-
sitivity reactions reported in a randomized comparative trial
with paclitaxel albumin bound given every 3 weeks [15].
Paclitaxel monotherapy or combination therapies with
trastuzumab represent important options for the treatment
of early stage and metastatic breast cancer. Recent in vitro
reports suggest dexamethasone may inhibit paclitaxel
cytotoxicity or may interfere with trastuzumab-induced cell
growth inhibition [16, 17]. Together these findings support
the use of nonsteroid-containing premedication regimens.
In the current study, the incidence of infusion hypersensi-
tivity reaction (all grades) with the first or second dose of
paclitaxel was observed to be 4% (n=3), and the incidence of
serious infusion hypersensitivity reactions (grade 3 or 4) to
be less than 1% (n=1), which is consistent with previous
reports [1, 3, 4]. We were unable to compare the results of
our primary endpoint (0 patients requiring rescue medication
after premedications were discontinued) to historical controls
since the true incidence of rescue medication usage after the
second dose has not been characterized in the literature.
Interestingly, in our trial, a subset of nine (13%) patients
who despite having no infusion hypersensitivity reactions felt
that the late side effects attributed to paclitaxel (such as plantar
skin peeling, lower extremity rash and facial burning, rash on
dorsal arm, itching, indigestion, and allergic rhinitis) could be
ameliorated by premedications and requested that they be
continued (n=3) or resumed after stopping (n=6). Following
discontinuation of dexamethasone, no patients requested an
antiemetic premedication be added for nausea.
There are several limitations to this trial including a small
sample size and lack of a control arm. Quality of life, nursing
convenience, patient time spent in the infusion suite, and cost
data, collected before and after paclitaxel premedication
discontinuation also would have been of interest. A small
number (15%) of patients included in the primary analysis
received 175 mg/m2 doses, and although our study was not
powered to look at differences between paclitaxel doses,
this approach appears to be applicable regardless of
paclitaxel dose. The upper limit of the 95% CI (5.3%)
exceeds what was previously stated as an acceptable rate of
rescue medication usage (5%), however this can be
attributed to sample size. If three more subjects would
have been included in the primary analysis, then the upper
bound of the one-sided 95% CI would have been 5.0%;
recall that six patients not included in primary analysis had
premedications resumed in later cycles despite not experi-
encing an infusion hypersensitivity reaction after paclitaxel
premedications were stopped. As the incidence of rescue
medication usage in this trial was 0%, these results support
the research hypothesis.
As the usage of weekly paclitaxel administration has
increased due to improved efficacy and/or less toxicity, the
necessity for repeated doses of premedications to prevent
infusion hypersensitivity reactions with every dose and the
safety of discontinuing these premedications are relevant
questions. Hence, our study is important given the simplified
approach that prospectively explored stopping premedications
after two doses.
In summary, these results showed no use of rescue
medication to treat infusion hypersensitivity reactions in 55
patients receiving varying doses and schedules of paclitaxel
after premedications were discontinued, with a 95% CI of 0–
5.3%. Based on these results, the standard practice of
premedicating patients prior to every dose of paclitaxel may
include the option of discontinuing premedications with the
third and subsequent doses in patients who had not experienced
a prior infusion hypersensitivity reaction. This approach looks
promising but must be validated with a larger, prospective,
randomized trial. Subsequent prospective trials should also
include validated questionnaires to assess the side effects of
standard premedications and the degree of interference that
these symptoms cause on quality of life.
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